← Back to Search

Nipple Aspirate Fluid Detection for Breast Cancer

N/A
Waitlist Available
Led By William Carson, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial studies collecting nipple fluid to detect breast cancer in women. The fluid is tested for cancer-related proteins using a new technology, which may find cancer earlier than current methods like mammograms.

Who is the study for?
This trial is for women over a year removed from pregnancy or lactation, with current breast cancer diagnosis or healthy subjects without any cancer. Healthy participants must have had a recent non-suspicious breast exam/mammogram. Exclusions include men, those pregnant/lactating within the last year, and anyone with cancers other than breast.
What is being tested?
The study is examining nipple aspirate fluid to see if it's more effective at early detection of breast cancer compared to traditional screening methods like mammograms and clinical exams.
What are the potential side effects?
Since this trial involves collecting fluid samples and not testing a drug or therapy, there are minimal side effects expected beyond potential discomfort or bruising from the aspiration procedure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Biomarkers expression levels

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (nipple aspiration fluid)Experimental Treatment2 Interventions
Participants and healthy volunteers undergo collection of nipple aspirate fluid from both breasts.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~2030

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Breast cancer treatments work through various mechanisms to target and eliminate cancer cells. Surgery physically removes the tumor, while radiation uses high-energy waves to destroy cancerous tissue. Chemotherapy involves drugs that kill rapidly dividing cells, including cancer cells. Hormone therapy blocks hormones like estrogen that fuel certain breast cancers, and targeted therapy uses drugs to specifically target cancer cell molecules, such as HER2 proteins. Understanding these mechanisms is crucial for patients as it helps in selecting the most effective treatment plan and managing side effects. Early detection methods like nipple aspirate fluid can identify biomarkers, potentially allowing for earlier and more personalized treatment interventions.
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available evidence and clinical implications.Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,938 Previous Clinical Trials
41,023,168 Total Patients Enrolled
943 Trials studying Breast Cancer
1,443,257 Patients Enrolled for Breast Cancer
Ohio State University Comprehensive Cancer CenterLead Sponsor
340 Previous Clinical Trials
293,308 Total Patients Enrolled
23 Trials studying Breast Cancer
2,902 Patients Enrolled for Breast Cancer
William Carson, MD4.86 ReviewsPrincipal Investigator - Ohio State University Comprehensive Cancer Center
5 Previous Clinical Trials
154 Total Patients Enrolled
1 Trials studying Breast Cancer
99 Patients Enrolled for Breast Cancer
5Patient Review
I couldn't have been more pleased.

Media Library

Aspiration of Breast 2023 Treatment Timeline for Medical Study. Trial Name: NCT03715959 — N/A
~0 spots leftby Dec 2024